Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SF1126 in Relapsed/Refractory Neuroblastoma
NCT02337309Phase 1Terminated
- Sponsor
- New Advances in Neuroblastoma Therapy
- Start
- Jul 2015
- Primary completion
- May 2018
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SF1126 in neuroblastoma, sponsored by New Advances in Neuroblastoma Therapy. Primary endpoint: Toxicities at 6 months. Started Jul 2015; status: terminated.
02
Drugs
SF1126
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT02337309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02337309.